Travere Therapeutics (TVTX) Leases: 2019-2025
Historic Leases for Travere Therapeutics (TVTX) over the last 7 years, with Sep 2025 value amounting to $11.5 million.
- Travere Therapeutics' Leases fell 26.80% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year decrease of 26.80%. This contributed to the annual value of $14.3 million for FY2024, which is 20.85% down from last year.
- Per Travere Therapeutics' latest filing, its Leases stood at $11.5 million for Q3 2025, which was down 7.07% from $12.3 million recorded in Q2 2025.
- Travere Therapeutics' 5-year Leases high stood at $25.0 million for Q1 2021, and its period low was $11.5 million during Q3 2025.
- In the last 3 years, Travere Therapeutics' Leases had a median value of $16.5 million in 2024 and averaged $16.1 million.
- Data for Travere Therapeutics' Leases shows a maximum YoY plummeted of 32.96% (in 2021) over the last 5 years.
- Over the past 5 years, Travere Therapeutics' Leases (Quarterly) stood at $23.2 million in 2021, then dropped by 9.47% to $21.0 million in 2022, then fell by 14.00% to $18.1 million in 2023, then dropped by 20.85% to $14.3 million in 2024, then dropped by 26.80% to $11.5 million in 2025.
- Its Leases was $11.5 million in Q3 2025, compared to $12.3 million in Q2 2025 and $13.2 million in Q1 2025.